| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Departments of Histology and Embryology*
and Pulmonary Medicine,
School of Medicine,
University of Athens, Athens, Greece; Roy
Castle,
International Center for Lung Cancer
Research, Liverpool, United Kingdom; and Department of Molecular
Genetics,§
Wistar Institute,
Philadelphia, Pennsylvania
The p16-pRb and p53-MDM2 pathways represent vital cell cycle checkpoints. Recent studies provide evidence that these pathways are directly linked via MDM2-pRb interaction and p53 suppression of the RB1 gene. In the present study we investigated the alterations of this G1 phase protein network using immunohistochemical and molecular methods in a series of 68 non-small-cell lung carcinomas (NSCLCs) and correlated the findings with clinicopathological features and prognosis of the patients. Aberrant expression (Ab) of p16 and pRb was observed in 33 (49%) and 27 (40%) of the carcinomas, respectively. Analysis of the region that encodes for p16 by deletion mapping, a polymerase chain reaction (PCR)-based methylation assay and PCR single-strand conformation polymorphism (SSCP) analysis revealed that deletions and transcriptional silencing by methylation might represent the main mechanisms of CDKN2/p16ink4a inactivation in NSCLCs. The results of deletion mapping also suggest that other tumor suppressor genes may reside at the 9p21–22 region, which encodes for CDKN2/MTS1/p16ink4a, p14ARF, and MTS2/p15ink4b. In addition, microsatellite instability was observed with a frequency of 16% in the 9p21–22 chromosome area. Overexpression (P) of p53 and MDM2 proteins was found in 39 (58%) and 47 (70%) of the cases, respectively. A highly significant association was observed between p53 overexpression and p53 mutations (P = 0.006). Statistical analysis of the expression patterns of the biologically relevant molecules (p16/pRb, p53/MDM2, MDM2/pRb, and p53/pRb) showed coincident overexpression of p53 and MDM2 (P = 0.04) and that abnormal pRb was correlated with elevated levels of MDM2 (P = 0.013) and p53 (P = 0.01), respectively. We suggest that deregulated expression of these molecules may act synergistically. An important finding of the study was that multiple impairments (three and four molecules affected) of the p16/pRb/p53/MDM2 network occurred in a large proportion (43%) of the carcinomas. This finding in addition to the absence of correlation with clinical stage of the tumors suggests that multiple hits of this network may be a relatively early event in the development of a subset of NSCLCs. The relationship between the factors examined in the present study, clinicopathological features, and survival of the patients did not reveal any significant correlations with the exception of smoking, which was associated with microsatellite alterations (loss of heterozygosity and microsatellite instability) at the 9p21–22 locus (P = 0.04) and the immunophenotypes p53(P)/MDM2(P) (P = 0.04) and p16(Ab)/pRb(Ab)/p53(P)/MDM2(P) (P = 0.03), respectively. We suggest that in a subset of NSCLCs, simultaneous deregulation of the members of this network may represent one way of initiating the oncogenic procedure whereas in other NSCLC subgroups alternative pathways may play this role.
This article has been cited by other articles:
 |
|
 |
|
  M. Liontos, K. Niforou, G. Velimezi, K. Vougas, K. Evangelou, K. Apostolopoulou, R. Vrtel, A. Damalas, P. Kontovazenitis, A. Kotsinas, et al. Modulation of the E2F1-Driven Cancer Cell Fate by the DNA Damage Response Machinery and Potential Novel E2F1 Targets in Osteosarcomas Am. J. Pathol., July 1, 2009; 175(1): 376 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Joubel, R. J. Chalkley, K. F. Medzihradszky, H. Hondermarck, and A. L. Burlingame Identification of New p53 Acetylation Sites in COS-1 Cells Mol. Cell. Proteomics, June 1, 2009; 8(6): 1167 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Hung, P. Boffetta, F. Canzian, N. Moullan, N. Szeszenia-Dabrowska, D. Zaridze, J. Lissowska, P. Rudnai, E. Fabianova, D. Mates, et al. Sequence Variants in Cell Cycle Control Pathway, X-ray Exposure, and Lung Cancer Risk: A Multicenter Case-Control Study in Central Europe Cancer Res., August 15, 2006; 66(16): 8280 - 8286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C-Q Zhu, W Shih, C-H Ling, and M-S Tsao Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J. Clin. Pathol., August 1, 2006; 59(8): 790 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Karakaidos, S. Taraviras, L. V. Vassiliou, P. Zacharatos, N. G. Kastrinakis, D. Kougiou, M. Kouloukoussa, H. Nishitani, A. G. Papavassiliou, Z. Lygerou, et al. Overexpression of the Replication Licensing Regulators hCdt1 and hCdc6 Characterizes a Subset of Non-Small-Cell Lung Carcinomas: Synergistic Effect with Mutant p53 on Tumor Growth and Chromosomal Instability--Evidence of E2F-1 Transcriptional Control over hCdt1 Am. J. Pathol., October 1, 2004; 165(4): 1351 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-S. Hsu, Y.-C. Wang, R.-C. Tseng, J.-W. Chang, J.-T. Chen, C.-M. Shih, C.-Y. Chen, and Y.-C. Wang CpG Island Methylation Is Responsible for p14ARF Inactivation and Inversely Correlates with p53 Overexpression in Resected Non-Small Cell Lung Cancer Clin. Cancer Res., July 15, 2004; 10(14): 4734 - 4741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-Y. Cao, Y. Lee, N.-P. Feng, R. A. Al-Qawasmeh, S. Viau, X.-P. Gu, L. Lau, H. Jin, M. Wang, A. Vassilakos, et al. NC381, a Novel Anticancer Agent, Arrests the Cell Cycle in G0-G1 and Inhibits Lung Tumor Cell Growth in Vitro and in Vivo J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 538 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mariatos, J. Bothos, P. Zacharatos, M. K. Summers, D. M. Scolnick, C. Kittas, T. D. Halazonetis, and V. G. Gorgoulis Inactivating Mutations Targeting the chfr Mitotic Checkpoint Gene in Human Lung Cancer Cancer Res., November 1, 2003; 63(21): 7185 - 7189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kotsinas, K. Evangelou, P. Zacharatos, C. Kittas, and V. G. Gorgoulis Proliferation, but Not Apoptosis, Is Associated with Distinct {beta}-Catenin Expression Patterns in Non-Small-Cell Lung Carcinomas : Relationship with Adenomatous Polyposis Coli and G1-to S-Phase Cell-Cycle Regulators Am. J. Pathol., November 1, 2002; 161(5): 1619 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kang, L. L. Ozbun, J. Angdisen, T. W. Moody, M. Prentice, B. A. Diwan, and S. B. Jakowlew Altered expression of G1/S regulatory genes occurs early and frequently in lung carcinogenesis in transforming growth factor-{beta}1 heterozygous mice Carcinogenesis, July 1, 2002; 23(7): 1217 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gessner, U. Liebers, H. Kuhn, P. Stiehl, C. Witt, J. Schauer, and G. Wolff BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer Eur. Respir. J., January 1, 2002; 19(1): 134 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Simpson, S. J. Frost, J. E. Bicknell, J. C. Broome, A. M. McNicol, R. N. Clayton, and W. E. Farrell Aberrant expression of G1/S regulators is a frequent event in sporadic pituitary adenomas Carcinogenesis, August 1, 2001; 22(8): 1149 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Nicholson, N. T. Okby, M. A. Khan, J. A. Welsh, M. G. McMenamin, W. D. Travis, J. R. Jett, H. D. Tazelaar, V. Trastek, P. C. Pairolero, et al. Alterations of p14ARF, p53, and p73 Genes Involved in the E2F-1-mediated Apoptotic Pathways in Non-Small Cell Lung Carcinoma Cancer Res., July 1, 2001; 61(14): 5636 - 5643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sanchez-Beato, A. I. Saez, I. C. Navas, P. Algara, M. Sol Mateo, R. Villuendas, F. Camacho, A. Sanchez-Aguilera, E. Sanchez, and M. A. Piris Overall Survival in Aggressive B-Cell Lymphomas Is Dependent on the Accumulation of Alterations in p53, p16, and p27 Am. J. Pathol., July 1, 2001; 159(1): 205 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Gorgoulis, P. Zacharatos, G. Mariatos, T. Liloglou, S. Kokotas, N. Kastrinakis, A. Kotsinas, A. Athanasiou, P. Foukas, V. Zoumpourlis, et al. Deregulated Expression of c-mos in Non-Small Cell Lung Carcinomas: Relationship with p53 Status, Genomic Instability, and Tumor Kinetics Cancer Res., January 1, 2001; 61(2): 538 - 549. [Abstract] [Full Text]
|
|
|
|
|
|
M. Seike, A. Gemma, Y. Hosoya, S. Hemmi, Y. Taniguchi, Y. Fukuda, N. Yamanaka, and S. Kudoh Increase in the Frequency of p16INK4 Gene Inactivation by Hypermethylation in Lung Cancer during the Process of Metastasis and Its Relation to the Status of p53 Clin. Cancer Res., November 1, 2000; 6(11): 4307 - 4313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kersting, C. Friedl, A. Kraus, M. Behn, W. Pankow, and M. Schuermann Differential Frequencies of p16INK4a Promoter Hypermethylation, p53 Mutation, and K-ras Mutation in Exfoliative Material Mark the Development of Lung Cancer in Symptomatic Chronic Smokers J. Clin. Oncol., September 18, 2000; 18(18): 3221 - 3229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. N. ROM, J. G. HAY, T. C. LEE, Y. JIANG, and K.-M. TCHOU-WONG Molecular and Genetic Aspects of Lung Cancer Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1355 - 1367. [Full Text]
|
|
|
|
|
|
L. You, C.-T. Yang, and D. M. Jablons ONYX-015 Works Synergistically with Chemotherapy in Lung Cancer Cell Lines and Primary Cultures Freshly Made from Lung Cancer Patients Cancer Res., February 1, 2000; 60(4): 1009 - 1013. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
